Good to see their presence in Toronto. Perhaps it will lead to some awareness there. It is worth a visit to https://www.bloomburton.com/
As I reflect over the past 3 years the observations I can make are;
- The level of communications continues to increase significantly and now with a VP of Investor Relations I'm sure this will continue.
- The scientific discoveries re the MOA of apabetalone (rvx-208) continue in a very positive direction and it's multiple cascading effects have positive implications for many diseases...not just CVD, diabetes, CKD.
- But I think the central issue is the underlying incredible potential and value of Resverlogix and Zenith Epigenetics is their particular extra terminal and bromodomain (BET) inhibition platform and scaffold. They truly seem to be a knowledge company with many, many opportunities to tap into from their platform. And as BDAZ has pointed out other scaffolds and CEPT inhibitors have failed so far even though they have the big $ of BP backing them. Apabetalone resulted in 55% MACE reduction in post hocs.
Anyway, just ranting out loud again. We'll see where things go but I'm sure that on the science side it will be remarkable. Don did not hire a VP of IR for no reason and Mr Paradis would not have joined RVX without being quite convinced of the potential.
Cheers
Toinv
